Payment overview · 2025
General Payments
$227,946.49
236 reported records · 18 companies
Healthcare provider profile · identity verified
David C Mares, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · ANDERSON, IN · NPI 1396770335
Verified facts
What the public records show
CMS Open Payments records show David C Mares, MD received $227,946.49 in general payments during 2025 across 236 reported records.
AstraZeneca Pharmaceuticals LP accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fasenra, Nucala, Tezspire, Trelegy Ellipta, Xolair.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Fasenra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Tezspire by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xolair as an associated drug or biological on 11057 records involving 4008 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xolair by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HYQVIA as an associated drug or biological on 8878 records involving 3983 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Hyqvia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152,197.41 | 66.8% | 118 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $35,130.56 | 15.4% | 26 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $26,535.71 | 11.6% | 26 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $10,903.21 | 4.8% | 13 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $2,225.97 | 1.0% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $308.01 | 0.1% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $248.39 | 0.1% | 16 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $68.36 | 0.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.50 | 0.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.54 | 0.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.82 | 0.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.32 | 0.0% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $38.16 | 0.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.44 | 0.0% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $23.97 | 0.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.29 | 0.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.86 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $208,595.76 | 84 |
| Honoraria | $10,000.00 | 3 |
| Food and Beverage | $6,411.41 | 135 |
| Travel and Lodging | $2,921.94 | 13 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $66,721.96 | 47 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43,097.53 | 30 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $35,130.56 | 26 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $26,438.63 | 25 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $21,827.35 | 24 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20,688.33 | 22 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $10,903.21 | 13 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $2,294.33 | 8 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $226.65 | 15 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $170.64 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $137.19 | 8 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $43.82 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.32 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.32 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.32 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FASENRA fasenra |
2025 | Fasenra | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 347 | exact normalized | Medicare Part D |
| Xolair xolair |
2025 | Xolair | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Xolair open payments reported associated product |
CMS Open Payments — General Payments 11057 supporting records · 4008 recipient NPIs · example record 1211488440 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
347 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | HYQVIA open payments reported associated product |
CMS Open Payments — General Payments 8878 supporting records · 3983 recipient NPIs · example record 1223616272 |
Hyqvia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 501 | 146 |
| Azithromycin | Azithromycin | 465 | 162 |
| Prednisone | Prednisone | 432 | 192 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 347 | 64 |
| Montelukast Sodium | Montelukast Sodium | 283 | 70 |
| Cefuroxime | Cefuroxime Axetil | 179 | 125 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 152 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 52 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 140 | 38 |
| Omeprazole | Omeprazole | 101 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 101 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 92 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 88 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 86 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 23 |
| Eliquis | Apixaban | 78 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 74 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 17 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 51 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 49 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 45 | 13 |
| Tezspire | Tezepelumab-Ekko | 44 | suppressed |
| Furosemide | Furosemide | 43 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 43 | 17 |
| Fasenra Pen | Benralizumab | 36 | suppressed |
| Gabapentin | Gabapentin | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Dupixent Syringe | Dupilumab | 29 | suppressed |
| Fasenra | Benralizumab | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Xolair | Omalizumab | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 27 | suppressed |
| Nucala | Mepolizumab | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Epinephrine | Epinephrine | 23 | suppressed |
| Lisinopril | Lisinopril | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Hyqvia | Igg/Hyaluronidase,recombinant | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Isoniazid | Isoniazid | 11 | suppressed |
| Priftin | Rifapentine | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227,946.49 · 236 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACTHAR, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, DUPIXENT, FASENRA, GLASSIA, Hillrom - Monarch Airway Clearance System, NUCALA, OFEV, OPSUMIT, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, Xolair, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fasenra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error